JP2017002009A5 - - Google Patents

Download PDF

Info

Publication number
JP2017002009A5
JP2017002009A5 JP2015120508A JP2015120508A JP2017002009A5 JP 2017002009 A5 JP2017002009 A5 JP 2017002009A5 JP 2015120508 A JP2015120508 A JP 2015120508A JP 2015120508 A JP2015120508 A JP 2015120508A JP 2017002009 A5 JP2017002009 A5 JP 2017002009A5
Authority
JP
Japan
Prior art keywords
vitamin
acid
lactoferrin
immunostimulant
immunostimulant according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015120508A
Other languages
Japanese (ja)
Other versions
JP2017002009A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2015120508A priority Critical patent/JP2017002009A/en
Priority claimed from JP2015120508A external-priority patent/JP2017002009A/en
Publication of JP2017002009A publication Critical patent/JP2017002009A/en
Publication of JP2017002009A5 publication Critical patent/JP2017002009A5/ja
Pending legal-status Critical Current

Links

Claims (5)

ラクトフェリンと、下記(a)〜(e)からなる群より選ばれる少なくとも1種の成分とを有効成分として含有することを特徴とする免疫賦活剤。
(a)没食子酸及びクロロゲン酸から選ばれる少なくとも1種のポリフェノール
(b)甘藷、長命草、ヨモギ、松、葛、及びターミナリアから選ばれる少なくとも1種の植物素材
(c)アスパルテーム、麦芽糖、ショ糖脂肪酸エステル、フラクトオリゴ糖、トレハロース、還元パラチノース、還元麦芽糖、及びシェラックから選ばれる少なくとも1種の機能性添加剤
(d)アラニン、アルギニン、アスパラギン、アスパラギン酸、システイン、グルタミン、グルタミン酸、グリシン、ヒスチジン、イソロイシン、ロイシン、リジン、メチオニン、フェニルアラニン、プロリン、セリン、トレオニン、トリプトファン、チロシン、及びバリンから選ばれる少なくとも1種のアミノ酸
(e)ビタミンB1、ビタミンB2、ビタミンB6、ビタミンB12、ビタミンC、ビタミンD3、ビタミンE、パントテン酸ナトリウム、ナイアシン、葉酸、ビオチン、カルシウム、マンガン、亜鉛、鉄、銅、モリブデン、マグネシウム、及びクロムから選ばれる少なくとも1種のビタミン・ミネラル類
An immunostimulant comprising lactoferrin and at least one component selected from the group consisting of the following (a) to (e) as active ingredients.
(A) at least one polyphenol selected from gallic acid and chlorogenic acid (b) at least one plant material selected from sweet potato, long life grass, mugwort, pine, kuzu and terminaria (c) aspartame, maltose, sucrose fatty acid esters, fructooligosaccharides, trehalose, reduced palatinose, reduced maltose, and at least one functional additive selected from shellac (d) alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine , leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and at least one amino acid selected from valine (e) vitamin B1, vitamin B2, vitamin B6, vitamin 12, vitamin C, vitamin D3, vitamin E, sodium pantothenate, niacin, folic acid, biotin, calcium, manganese, zinc, iron, copper, molybdenum, magnesium, and at least one vitamin, minerals selected from chromium
ラクトフェリンと(a)〜(e)からなる群より選ばれる少なくとも1種の成分とからなる有効成分を添加して得たことを特徴とする請求項1記載の免疫賦活剤。   The immunostimulant according to claim 1, obtained by adding an active ingredient comprising lactoferrin and at least one component selected from the group consisting of (a) to (e). ラクトフェリン及び他の有効成分の配合質量比が、0.5:1〜70:1の範囲であることを特徴とする請求項1又は2記載の免疫賦活剤。   The immunostimulant according to claim 1 or 2, wherein the blending mass ratio of lactoferrin and other active ingredients is in the range of 0.5: 1 to 70: 1. 錠剤、カプセル剤、粉末剤、顆粒剤、又は液剤であることを特徴とする請求項1〜3のいずれか記載の免疫賦活剤。   The immunostimulant according to any one of claims 1 to 3, which is a tablet, capsule, powder, granule, or liquid. 請求項1〜4のいずれか記載の免疫賦活剤を摂取させることを特徴とする免疫賦活方法(ただし、医療行為を除く)。   An immunostimulation method (however, excluding medical practice) characterized by ingesting the immunostimulant according to any one of claims 1 to 4.
JP2015120508A 2015-06-15 2015-06-15 Immunostimulator Pending JP2017002009A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015120508A JP2017002009A (en) 2015-06-15 2015-06-15 Immunostimulator

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015120508A JP2017002009A (en) 2015-06-15 2015-06-15 Immunostimulator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019104532A Division JP6841444B2 (en) 2019-06-04 2019-06-04 Immunostimulant

Publications (2)

Publication Number Publication Date
JP2017002009A JP2017002009A (en) 2017-01-05
JP2017002009A5 true JP2017002009A5 (en) 2019-03-14

Family

ID=57751236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015120508A Pending JP2017002009A (en) 2015-06-15 2015-06-15 Immunostimulator

Country Status (1)

Country Link
JP (1) JP2017002009A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020122100A1 (en) * 2018-12-12 2020-06-18 森永乳業株式会社 Method for improving solubility of polymethoxy flavonoid
JP6734603B1 (en) * 2019-10-09 2020-08-05 株式会社東洋新薬 Oral composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038291A1 (en) * 2005-09-22 2007-04-05 Mitsui Norin Co., Ltd Black tea polyphenols and uses thereof
NZ555163A (en) * 2007-05-14 2010-05-28 Fonterra Co Operative Group Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
JP2012031089A (en) * 2010-07-30 2012-02-16 Shiibaion:Kk Immunostimulator

Similar Documents

Publication Publication Date Title
EA201591050A1 (en) IMIDAZOPIRIDINE CONNECTIONS
MX380541B (en) SUITABLE COMPOSITION TO PROTECT MICROORGANISMS.
WO2015164515A8 (en) Unit dose detergent compositions
WO2014116750A3 (en) Flavor composition and edible compositions containing same
PH12013501241A1 (en) A water soluble composition comprising curcumin having enhanced bioavailability and process thereof
WO2019023039A3 (en) Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances
BR112018001534A2 (en) mutant isocitrate dehydrogenase inhibitor idh1 r132h
MX369571B (en) Composition for preventing or treating fatty liver diseases.
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
WO2016140933A3 (en) Immediate release soluble ibuprofen compositions
EA201800027A1 (en) COMPOSITION OF SYNERGETIC DRINKS
WO2018108931A3 (en) Nutritional compositions containing butyrate and/or lactoferrin and uses thereof
JP2017014155A5 (en)
JP2016210757A5 (en)
EA201791380A1 (en) CROSSED POLYDIDIALLYLAMINE BASED COPOLYMERS FOR TREATMENT OF DIABETES TYPE 2
JP2017012144A5 (en)
JP2017008001A5 (en)
JP2017014164A5 (en)
WO2016178510A3 (en) Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3
JP2017007966A5 (en)
BR112017013269A2 (en) ? liquid pharmaceutical composition?
JP2016216373A5 (en)
MX2022006741A (en) Hdac inhibitor solid state forms.
TR201205317A2 (en) Effervescent formulations containing dexketoprofen.
EA201300947A1 (en) COMPOSITION FOR INCREASING STABILITY OF JOINTS AND / OR POSITIVE STABILITY